Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Experiment to measure the budget impact of digital medical devices launched in France

On March 24, 2023, the French National Authority for Health (HAS) announced a three-year experiment on the health economic evaluation of digital medical devices (DMD).

This experiment should make it possible to evaluate the budget impact (changes in the distribution of Social Insurance expenses, quantifying future savings) of DMDs.

Manufacturers claiming levels of added clinical value (ASA) ranging from major (I) to minor (IV) and an impact on the organization of care can voluntarily accompany their request for registration or renewal of registration of their DMD on the list of reimbursable products and services (LPPR) with a budget impact analysis.

This will allow manufacturers to provide the Economic Committee on Health Products (CEPS) with a budget impact analysis, validated by the HAS Economic and Public Health Evaluation Commission (CEESP), to present savings generated to the healthcare system to define the fairest possible pricing of their innovation.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.